The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic salivary gland cancers (R/M SGCs).
 
Bharat Burman
Employment - Janssen (I)
Stock and Other Ownership Interests - Janssen (I)
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Blueprint Medicines; Cota Healthcare; Eisai; Goldilocks; Lilly; Regeneron; UpToDate
Research Funding - Plexxikon; Regeneron
 
Lara Dunn
Consulting or Advisory Role - CUE Biopharma; CUE Biopharma; Regeneron
Research Funding - Eisai; Pfizer; Regeneron
 
James Vincent Fetten
No Relationships to Disclose
 
Loren S. Michel
Research Funding - Exelixis (Inst)
Travel, Accommodations, Expenses - Immunomedics
 
Luc G.T. Morris
Consulting or Advisory Role - Rakuten Aspyrian
Research Funding - AstraZeneca; Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - employer pending patent application, listed as inventor (Inst)
 
Irina Ostrovnaya
No Relationships to Disclose
 
Sofia Haque
Honoraria - Advance Medical
Consulting or Advisory Role - Advance Medical
 
David G. Pfister
Consulting or Advisory Role - Boehringer Ingelheim; Incyte
Research Funding - AstraZeneca (Inst); Atara Biotherapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Hookipa Pharma (Inst); Lilly (Inst); MedImmune (Inst); MeiraGTx (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
 
Alan Loh Ho
Consulting or Advisory Role - AffyImmune Therapeutics; AstraZeneca; Ayala Pharmaceuticals; Bristol-Myers Squibb; CureVac; CureVac; Eisai; Eisai; Exelixis; Genzyme; Kura Oncology; McGivney Global Advisors; Merck; Novartis; Prelude Therapeutics; Regeneron; Rgenta; Sanofi; Sun Pharma; TRM Oncology
Speakers' Bureau - Medscape; Novartis; Omniprex America
Research Funding - Allos Therapeutics; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Ayala Pharmaceuticals; Ayala Pharmaceuticals; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevar Therapeutics; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly; Merck; Novartis; Novartis; Novartis; Pfizer
Travel, Accommodations, Expenses - Ayala Pharmaceuticals; Ignyta; Janssen Oncology; Klus Pharma; Kura Oncology; Kura Oncology; Kura Oncology; Merck